Harding Loevner LP raised its position in shares of Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) by 91.7% during the third quarter, according to its most recent disclosure with the SEC. The firm owned 318,565 shares of the biopharmaceutical company’s stock after buying an additional 152,425 shares during the period. Harding Loevner LP owned approximately 0.30% of Regeneron Pharmaceuticals worth $128,070,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. IFP Advisors Inc boosted its stake in shares of Regeneron Pharmaceuticals by 32.3% in the second quarter. IFP Advisors Inc now owns 328 shares of the biopharmaceutical company’s stock worth $115,000 after buying an additional 80 shares during the period. Advisory Services Network LLC boosted its stake in shares of Regeneron Pharmaceuticals by 5,433.3% in the second quarter. Advisory Services Network LLC now owns 332 shares of the biopharmaceutical company’s stock worth $116,000 after buying an additional 326 shares during the period. Fuller & Thaler Asset Management Inc. acquired a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth approximately $140,000. Brave Asset Management Inc acquired a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth approximately $157,000. Finally, CIBC World Markets Inc. acquired a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth approximately $202,000. Institutional investors and hedge funds own 68.58% of the company’s stock.

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Shares of Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) traded down 1.75% during trading on Friday, reaching $397.48. 1,413,411 shares of the company’s stock traded hands. The company has a market capitalization of $41.59 billion, a price-to-earnings ratio of 62.01 and a beta of 1.79. The company has a 50 day moving average of $381.02 and a 200-day moving average of $388.09. Regeneron Pharmaceuticals Inc. has a 1-year low of $325.35 and a 1-year high of $587.38.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Friday, November 4th. The biopharmaceutical company reported $3.13 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.73 by $0.40. The company earned $1.22 billion during the quarter, compared to analysts’ expectations of $1.29 billion. Regeneron Pharmaceuticals had a return on equity of 21.51% and a net margin of 16.52%. The business’s revenue was up 7.3% on a year-over-year basis. During the same period in the prior year, the business posted $3.47 EPS. Equities analysts predict that Regeneron Pharmaceuticals Inc. will post $11.73 earnings per share for the current year.

A number of equities research analysts have recently commented on REGN shares. Vetr cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $473.05 target price for the company. in a research report on Monday, August 15th. Goldman Sachs Group Inc. reiterated a “buy” rating on shares of Regeneron Pharmaceuticals in a research report on Wednesday, August 10th. Zacks Investment Research upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $472.00 target price for the company in a research report on Tuesday, August 9th. Leerink Swann set a $511.00 target price on shares of Regeneron Pharmaceuticals and gave the company a “buy” rating in a research report on Saturday, August 6th. Finally, RBC Capital Markets reiterated a “buy” rating on shares of Regeneron Pharmaceuticals in a research report on Saturday, August 6th. One investment analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and twelve have assigned a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $468.87.

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 2,000 shares of the stock in a transaction on Tuesday, November 15th. The stock was sold at an average price of $429.34, for a total value of $858,680.00. Following the sale, the director now directly owns 36,500 shares of the company’s stock, valued at $15,670,910. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Joseph L. Goldstein sold 2,125 shares of the stock in a transaction on Monday, November 14th. The stock was sold at an average price of $450.00, for a total value of $956,250.00. Following the completion of the sale, the director now directly owns 15,125 shares in the company, valued at $6,806,250. The disclosure for this sale can be found here. Insiders own 10.40% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions.

5 Day Chart for NASDAQ:REGN

Receive News & Stock Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.